Clareo Health | Use of an Ultra-rapid BRCA1/2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest for Patients and Practitioners
Indication for oncogenetic consultation with a wide panel test including BRCA1/2 (gold standard) as part of the standard theranostic and diagnostic management of breast cancer.
The patient agrees to take part in the study, to follow all the study procedures and to complete the questionnaires sent during the consultation or by email.
Diagnosis of the disease ≤ 6 months
The patient must be affiliated to the social security system.
You may not be if
Concomitant disorder or condition likely to compromise understanding of study information or completion of questionnaires
Patients who do not have an email address and/or do not have internet access or tools to connect to the internet
Women who are pregnant, may become pregnant or are breast-feeding
Persons deprived of their liberty or under guardianship (including curatorship)
Inability to undergo trial monitoring for geographical, social or psychological reasons.
